An advanced anti-cancer drug developed in the Hefei high-tech zone – located in Hefei city, capital of East China's Anhui province – recently got an important green light in its development.

The treatment, called a dual-ligand coupled drug, is named CBP-1019 and it was developed by company Coherent Biopharma. It was granted permission on April 14 to undergo clinical trials by the Center for Drug Evaluation of the National Medical Products Administration.

CBP-1019 is used for the treatment of including, but not limited to, advanced lung cancer, advanced pancreatic cancer, advanced esophageal cancer, advanced colorectal cancer and advanced endometrial cancer.

Developed on Coherent Biopharma's second-generation Bi-XDC platform, CBP-1019 is said to have better plasma stability and operates in a wider therapeutic field.

Preclinical studies are reported to have shown that CBP-1019 has significant antitumor activity and a favorable safety profile.

In several tumor models – including lung cancer, ovarian cancer, pancreatic cancer, esophageal cancer and digestive tract cancer – CBP-1019 is said to have shown significant tumor suppressive effects and dose correlation, while the test animals showed no significant weight loss, demonstrating a good safety profile.

Founded in 2016, Coherent Biopharma is based in Suzhou city in East China's Jiangsu province and signed agreements with Hefei high-tech zone on Feb 20 to settle its new R&D center and production base there.

It boasts cutting-edge technologies for the development of multi-target drugs.